ArticleFrontiers in pharmacology2022
Real World Data in Health Technology Assessment of Complex Health Technologies.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Pooled it
- Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries.Clinical pharmacology and therapeutics · 2026Article
- Are Traditional Registries Becoming Obsolete in the Modern Digital Health Ecosystem?Journal of medical Internet research · 2026Article
- RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities.Therapeutic innovation & regulatory science · 2026Article
- A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence.Pharmacoepidemiology and drug safety · 2026Article
- Global Stakeholder Perspectives on Real-World Data and Evidence in Health Technology Assessment: An Exploratory Study.Healthcare (Basel, Switzerland) · 2026Article
- When should RWE studies be prioritized for reimbursement? Insights from the Canadian perspective.International journal of technology assessment in health care · 2026Article
- Bridging evidence worlds: policy and practice pathways for integrating clinical trials and real-world data in drug development and HTA.Frontiers in pharmacology · 2026Article
- Applicability of academic real-world data research in the case studies of the HTx project to practical health technology assessment work.Frontiers in pharmacology · 2026Article
- Key Stakeholders' Knowledge, Opinions, and Interests on Real-World Evidence in the Regulatory Process-Results of an EU-Wide Survey.Clinical and translational science · 2025Article
- Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology.Journal of comparative effectiveness research · 2025Article
- From Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access.PharmacoEconomics - open · 2025Article
- Methods for the health technology assessment of complex interventions: A scoping review.PloS one · 2025Article
- Use of transportability methods for real-world evidence generation: a review of current applications.Journal of comparative effectiveness research · 2024Review
- How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- The potential role of real-world evidence in Centers for Medicare & Medicaid Services' future price negotiations: Recommendations for a robust framework.Journal of managed care & specialty pharmacy · 2024Article
- Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review.Journal of medical Internet research · 2024Article
- Article
- Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments.PharmacoEconomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The available evidence on relative effectiveness and risks of new health technologies is often limited at the time of health technology assessment (HTA). Additionally, a wide variety in real-world data (RWD) policies exist among HTA organizations. This study assessed which challenges, related to the increasingly complex nature of new health technologies, make the acceptance of RWD most likely. A questionnaire was disseminated among 33 EUnetHTA member HTA organizations. The questions focused on accepted data sources, circumstances that allowed for RWD acceptance and barriers to acceptance. The questionnaire was validated and tested for reliability by an expert panel, and pilot-tested before dissemination
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.